Inhibition of Src Tyrosine Kinase as Treatment for Human Pancreatic Cancer Growing Orthotopically in Nude Mice
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Purpose: The Src family comprises a family of nonreceptor intracellular tyrosine kinases that mediate a variety of cellular pathways. Src kinases are overexpressed in a variety of human tumors, including cancer of the colon, breast, and pancreas, and they are an integral part of tumor cell signaling pathways associated with migration, proliferation, adhesion, and angiogenesis. Experimental Design: We investigated whether the blockade of Src kinase by daily oral administration of the novel Src tyrosine kinase inhibitor AZM475271 [kindly provided by AstraZeneca (Macclesfield, United Kingdom)], alone or in combination with intraperitoneal gemcitabine, can inhibit growth and metastasis of orthotopically implanted human pancreatic carcinoma cells in nude mice. Results: Treatment with AZM475271 alone reduced the primary pancreatic tumor volume by approximately 40%, whereas AZM475271 plus gemcitabine reduced tumor volume by 90%. Furthermore, treatment with AZM475271 and gemcitabine significantly reduced metastasis: none of eight animals who received the combination treatment had lymph node or liver metastases, compared with five of five and three of five animals, respectively, in the control group (P = 0.001). Src inhibition by AZM475271 (alone or with gemcitabine) was associated with significantly reduced tumor cell proliferation, decreased tumor microvessel density, and increased apoptosis in vivo. Moreover, these effects were all significantly increased when gemcitabine was combined with AZM475271 compared with gemcitabine alone. Conclusions: Src inhibition by AZM475271, either alone or in combination with gemcitabine, demonstrated significant antitumor and antimetastatic activity in an orthotopic nude mouse model for human pancreatic cancer. The combination of AZM475271 with gemcitabine sensitized tumor cells to the cytotoxic effect of gemcitabine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pengetnze, Y., Steed, M., Roby, K. F., Terranova, P. F., & Taylor, C. C. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.08.012 · Cited by 107
Cited by
Tumor metastasis: mechanistic insights and clinical challenges
Steeg, P. S. (2006) · Nature Medicine · doi:10.1038/nm1469 · Cited by 2,134
Tumor-stroma interactions in pancreatic ductal adenocarcinoma
Mahadevan, D., & Von Hoff, D. D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0686 · Cited by 601
The Role of Src in Solid Tumors
Wheeler, D. L., Iida, M., & Dunn, E. F. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0009 · Cited by 346
“Abrogating Src signaling has been shown to restore sensitivity to gemcitabine in tumor and tissue transplants cell lines derived from the pancreas [45,46,88].”
BackgroundAnnexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repair
Leoni, G., Alam, A., Neumann, P.-A., Lambeth, J. D., Cheng, G., McCoy, J., Hilgarth, R. S., Kundu, K., Murthy, N., Kusters, D., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65831 · Cited by 295
SKI-606, a Src/Abl Inhibitor with In vivo Activity in Colon Tumor Xenograft Models
Golas, J. M., Lucas, J., Etienne, C., Golas, J., Discafani, C., Sridharan, L., Boghaert, E., Arndt, K., Ye, F., Boschelli, D. H., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2484 · Cited by 134
Metadata
- Authors
- Yezhelyev, M. V., Koehl, G., Guba, M., Brabletz, T., Jauch, K.-W., Ryan, A., Barge, A., Green, T., Fennell, M., & Bruns, C. J.
- Venue
- Clinical Cancer Research
- Published
- 2004-12-01
- Volume
- 10
- Issue
- 23
- Pages
- 8028-8036
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2090805907
- Cited by
- 134
- References
- 1
- FWCI
- 6.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of Src Tyrosine Kinase as Treatment for Human Pancreatic Cancer Growing Orthotopically in Nude Mice. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-04-0621
- The paper
- Yezhelyev, M. V., Koehl, G., Guba, M., Brabletz, T., Jauch, K.-W., Ryan, A., Barge, A., Green, T., Fennell, M., & Bruns, C. J. (2004). Inhibition of Src Tyrosine Kinase as Treatment for Human Pancreatic Cancer Growing Orthotopically in Nude Mice. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-04-0621
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.